Abstract
Simvastatin, 10-40 mg/d (n = 11), bezafibrate, 600 mg/d (n = 6), and gemfibrozil, 1200 mg/d (n = 5) were administered for 12 weeks after a 4-week placebo period to subjects with initial plasma levels (mg/100 ml. mean +/- SD) of cholesterol (346 +/- 77), and of triglycerides (180 +/- 54). Total LDL-C plasma concentration was lowered 32% by simvastatin and 35% by bezafibrate, but only bezafibrate diminished the triglyceride (41%) and increased HDL-C plasma levels (35%). Plasma lipoprotein fractions obtained by discontinuous gradient ultracentrifugation, namely, VLDL, lighter LDL (LDL-1), heavier LDL (LDL-2) and bulk HDL were chemically analyzed. Simvastatin and bezafibrate significantly diminished the quantity of VLDL and LDL-1 particles, although barely modifying their composition. Neither drug influenced the LDL-2 plasma concentration. Bezafibrate increased the total plasma HDL level little interfering with its chemical composition. Gemfibrozil was the least effective of all drugs but decreased the lipid and protein contents and their ratios in VLDL and LDL-2.
References
May 12, 1975·Analytical Biochemistry·T G RedgraveC E West
Feb 1, 1990·Journal of Internal Medicine·G L VegaS M Grundy
Jun 1, 1990·Atherosclerosis·H H NewnhamP J Barter
Feb 1, 1986·European Journal of Clinical Investigation·D GavishS Eisenberg
Jul 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·J C GibsonH C Seftel
Jul 1, 1987·Arteriosclerosis : an Official Journal of the American Heart Association, Inc·T A MuslinerR M Krauss
May 24, 1983·Biochimica Et Biophysica Acta·R W Mahley, T L Innerarity
Apr 1, 1984·Proceedings of the National Academy of Sciences of the United States of America·S M Grundy, D W Bilheimer
Dec 1, 1984·The Journal of Clinical Investigation·J ShepherdH G Morgan
Jul 1, 1983·Proceedings of the National Academy of Sciences of the United States of America·D W BilheimerJ L Goldstein
Citations
Nov 1, 1995·Clinical Cardiology·E BruckertF Baigts
Jan 1, 1993·Lipids·B GeorgesJ Bézard
Jun 16, 2006·Cardiovascular Drugs and Therapy·Manfredi Rizzo, Kaspar Berneis
Jun 17, 2008·Cardiovascular Drugs and Therapy·Fergus McTaggart, Peter Jones
Jun 6, 1994·The American Journal of Medicine·D J BetteridgeD I Rees-Jones
Sep 30, 1994·Atherosclerosis·P M CliftonP J Nestel
Apr 1, 1994·Atherosclerosis·Y HommaH Nakamura
Jul 8, 1998·European Journal of Pharmacology·M AlegretJ C Laguna
Feb 13, 2001·Atherosclerosis·I PintaricI Lusić
Nov 15, 1996·Atherosclerosis·B R KrauseC L Bisgaier
Apr 27, 1999·Atherosclerosis·L LagrostP Gambert
Apr 1, 1997·Journal of the American College of Nutrition·I GirouxH Jacques
Jul 29, 2003·Journal of Cardiovascular Pharmacology·Vasilis TsimihodimosMoses Elisaf
May 1, 1993·European Journal of Clinical Investigation·H A KleinveldA F Stalenhoef
May 24, 2007·Current Medical Research and Opinion·Manfredi Rizzo, Kaspar Berneis
Jun 6, 1994·The American Journal of Medicine·H GretenH Eskötter
Dec 24, 2005·QJM : Monthly Journal of the Association of Physicians·M Rizzo, K Berneis